NPPB and hydrops fetalis: It is notable that in the STEP-HFpEF programme, there were fewer cardiac-related SAEs in the semaglutide group compared with placebo, along with decongestive effects suggested by greater reductions in NT-proBNP, fewer HF events, and lower loop diuretic dose requirements.